J. David Owens
President & CEO
Rob Gensure, MD, PhD
Chief Medical Officer
Robyn Goforth, PhD
Chief Scientific Officer
For more information about BiologicsMD, please contact:
Regulatory and Clinical
3805 Old Easton Road
Doylestown, PA 18902
R&D and Manufacturing
535 W Research Center Blvd, Suite 135
Fayetteville, AR 72701
BiologicsMD is an early stage therapeutic development company focused on developing highly-targeted or ‘smart’ therapies for the treatment of hair loss diseases and conditions, as well as severe bone disorders. The company is developing a series of recombinant fusion proteins that provide powerful stimulatory effects directly to the target receptors at the point of disease – and do so with sustained therapeutic exposure in either a single dose or very infrequent dosing regimens. The company is working on formulation and delivery vehicles that can accommodate parenteral, local, and topical administration.
Technology and Therapeutic Focus
BiologicsMD’s core technology consists of the manufacturing and development of therapeutic recombinant fusion proteins. The first pharmaceutical protein, PTH-CBD, is the fusion of the active domain of parathyroid hormone (amino acids 1-33) coupled to a collagen binding domain derived from ColH collagenase. The collagen binding domain (CBD) allows for the protein to distribute to the skin where the PTH (1-33) domain stimulates the hair follicles and restores hair growth.
BiologicsMD has three programs focused on the prevention of hair loss and restoration of hair growth that result from various forms of alopecia. Two additional assets are being developed for the treatment of severe bone disorders with spinal fusion, and prevention and treatment of breast cancer metastasis to the bone as initial target indications.